PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 137 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 0.37 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $382,000 | -27.2% | 100,482 | -2.7% | 0.00% | – |
| Q4 2019 | $525,000 | 0.0% | 103,234 | -0.5% | 0.00% | -100.0% |
| Q3 2019 | $525,000 | -66.6% | 103,785 | -59.3% | 0.00% | 0.0% |
| Q2 2019 | $1,573,000 | +38.8% | 254,909 | +4.4% | 0.00% | 0.0% |
| Q1 2019 | $1,133,000 | +9.8% | 244,265 | -0.6% | 0.00% | 0.0% |
| Q4 2018 | $1,032,000 | -35.3% | 245,655 | -3.5% | 0.00% | 0.0% |
| Q3 2018 | $1,596,000 | -14.8% | 254,619 | +9.3% | 0.00% | -50.0% |
| Q2 2018 | $1,873,000 | +7.2% | 232,984 | -0.6% | 0.00% | 0.0% |
| Q1 2018 | $1,748,000 | +47.8% | 234,314 | +17.8% | 0.00% | +100.0% |
| Q4 2017 | $1,183,000 | -20.2% | 198,852 | -1.3% | 0.00% | 0.0% |
| Q3 2017 | $1,483,000 | +6.9% | 201,523 | -1.3% | 0.00% | 0.0% |
| Q2 2017 | $1,387,000 | -29.3% | 204,202 | -1.7% | 0.00% | -50.0% |
| Q1 2017 | $1,962,000 | +7.6% | 207,837 | -1.5% | 0.00% | 0.0% |
| Q4 2016 | $1,823,000 | +29.9% | 211,010 | -4.8% | 0.00% | +100.0% |
| Q3 2016 | $1,403,000 | – | 221,644 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
| Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
| FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
| J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
| EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
| Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |